Spyre Therapeutics stock dropped sharply in early trading, sliding 11.7% in pre-market action after the company disclosed topline findings from the rheumatoid arthritis (RA) sub-study of its Phase 2 SKYWAY basket trial testing SPY072, the firm's anti-TL1A antibody candidate.
According to the announcement, both dose levels of SPY072 produced statistically significant improvements compared with placebo on at least one efficacy endpoint. The high dose achieved a 63% ACR20 response rate versus 43% for placebo. Despite those signals of clinical activity, the overall magnitude of benefit did not reach Spyre's internal threshold to move SPY072 forward as a standalone RA therapy. As a result, the company said it will not continue developing SPY072 as a monotherapy for rheumatoid arthritis.
Trading activity reflected investor disappointment. Selling began in after-hours trading on Tuesday and intensified into Wednesday's pre-market session, where the stock was quoted at 94.76, down 12.60 points or roughly 11.74% from a prior close of 107.36. The market response suggests the RA program had been viewed as a near-term, high-profile catalyst within Spyre's readout schedule branded as "6 in '26."
On the analyst front, Wedbush held its Outperform rating and maintained a $130 price target, indicating some analysts continue to place value on the company's remaining pipeline and balance-sheet position.
Market context underlined the company-specific nature of the move. The broader indexes were essentially flat - the S&P 500 was nearly unchanged, the Nasdaq was down about 0.2%, and the Dow was marginally positive - implying the pressure on Spyre's shares was driven by the clinical news rather than sector- or macro-driven selling.
Spyre's development calendar still lists additional Phase 2 SKYWAY readouts for SPY072 in psoriatic arthritis and axial spondyloarthritis expected in the fourth quarter of 2026. The company also has more data due from its SKYLINE ulcerative colitis program, with those results slated for September. Management contends that the RA sub-study outcomes validate TL1A inhibition as a mechanism of action and support exploration of SPY072 in combination regimens and in other autoimmune indications.
The sharp pre-market decline appears to reflect a market re-evaluation of SPY072's near-term risk profile for rheumatology. Investors will likely look to weigh the remaining 2026 catalysts - including the two SKYWAY readouts and SKYLINE ulcerative colitis data - against the setback in the RA monotherapy program when deciding whether the stock can stabilize.
Clear summary
Spyre reported statistically significant efficacy signals for SPY072 in its RA sub-study, including a 63% ACR20 rate for the higher dose versus 43% for placebo, but the results fell short of the company's internal threshold to support advancing the drug as an RA monotherapy. The stock fell sharply in after-hours and pre-market trading as investors reassessed the near-term outlook for the rheumatology franchise.